Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]Copanlisib in Healthy Males
NCT02119221Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copanlisib in follicular lymphoma (FL), sponsored by Bayer. Primary endpoints: Maximum Plasma Concentration of Copanlisib up to 336 hours, Area Under the Curve of Copanlisib up to 336 hours and 6 more. Started Feb 2014; status: completed.
02
Drugs
copanlisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02119221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02119221.